News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
786,244 Results
Type
Article (55818)
Company Profile (519)
Press Release (729890)
Multimedia
Podcasts (161)
Webinars (25)
Section
Business (218784)
Career Advice (2896)
Deals (37583)
Drug Delivery (143)
Drug Development (87683)
Employer Resources (192)
FDA (17480)
Job Trends (16204)
News (371895)
Policy (35920)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2943)
Academic (1)
Accelerated approval (41)
Adcomms (33)
Allergies (163)
Alliances (53590)
ALS (191)
Alzheimer's disease (1811)
Antibody-drug conjugate (ADC) (369)
Approvals (17691)
Artificial intelligence (610)
Autoimmune disease (189)
Automation (46)
Bankruptcy (391)
Best Places to Work (12331)
BIOSECURE Act (22)
Biosimilars (209)
Biotechnology (357)
Bladder cancer (176)
Brain cancer (67)
Breast cancer (688)
Cancer (5286)
Cardiovascular disease (468)
Career advice (2455)
Career pathing (43)
CAR-T (309)
CDC (65)
Celiac Disease (2)
Cell therapy (835)
Cervical cancer (39)
Clinical research (74578)
Collaboration (1937)
Company closure (4)
Compensation (1230)
Complete response letters (79)
COVID-19 (2951)
CRISPR (110)
C-suite (964)
Cystic fibrosis (155)
Data (6660)
Decentralized trials (2)
Denatured (50)
Depression (160)
Diabetes (543)
Diagnostics (7133)
Digital health (51)
Diversity (13)
Diversity, equity & inclusion (47)
Drug discovery (293)
Drug pricing (220)
Drug shortages (31)
Duchenne muscular dystrophy (258)
Earnings (93897)
Editorial (68)
Employer branding (24)
Employer resources (165)
Events (127371)
Executive appointments (1066)
FDA (20802)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (26)
Funding (1619)
Gene editing (231)
Generative AI (53)
Gene therapy (699)
GLP-1 (1124)
Government (5211)
Grass and pollen (8)
Guidances (387)
Healthcare (20294)
HIV (74)
Huntington's disease (52)
IgA nephropathy (90)
Immunology and inflammation (304)
Immuno-oncology (75)
Indications (134)
Infectious disease (3260)
Inflammatory bowel disease (215)
Inflation Reduction Act (17)
Influenza (133)
Intellectual property (267)
Interviews (561)
IPO (17349)
IRA (59)
Job creations (4235)
Job search strategy (1993)
JPM (70)
Kidney cancer (20)
Labor market (93)
Layoffs (633)
Leadership (44)
Legal (8798)
Liver cancer (102)
Longevity (19)
Lung cancer (712)
Lymphoma (394)
Machine learning (47)
Management (63)
Manufacturing (882)
MASH (184)
Medical device (14513)
Medtech (14577)
Mergers & acquisitions (21344)
Metabolic disorders (1440)
mRNA (195)
Multiple sclerosis (178)
NASH (23)
Neurodegenerative disease (378)
Neuropsychiatric disorders (106)
Neuroscience (3210)
Neurotech (1)
NextGen: Class of 2026 (7270)
Non-profit (4943)
Now hiring (70)
Obesity (696)
Opinion (335)
Ovarian cancer (175)
Pain (228)
Pancreatic cancer (250)
Parkinson's disease (314)
Partnered (34)
Patents (542)
Patient recruitment (555)
Peanut (65)
People (64354)
Pharmaceutical (94)
Pharmacy benefit managers (33)
Phase 1 (23254)
Phase 2 (32724)
Phase 3 (24364)
Pipeline (6098)
Policy (348)
Postmarket research (2941)
Preclinical (9978)
Press Release (70)
Prostate cancer (270)
Psychedelics (59)
Radiopharmaceuticals (316)
Rare diseases (1004)
Real estate (6542)
Recruiting (77)
Regulatory (26847)
Reports (58)
Research institute (2669)
Resumes & cover letters (458)
Rett syndrome (31)
RNA editing (21)
RSV (86)
Schizophrenia (164)
Series A (274)
Series B (205)
Service/supplier (13)
Sickle cell disease (110)
Special edition (28)
Spinal muscular atrophy (171)
Sponsored (45)
Startups (3987)
State (2)
Stomach cancer (21)
Supply chain (114)
Tariffs (98)
The Weekly (109)
Vaccines (1151)
Venture capital (102)
Weight loss (467)
Women's health (105)
Worklife (23)
Date
Today (159)
Last 7 days (847)
Last 30 days (3155)
Last 365 days (31687)
2026 (5569)
2025 (31917)
2024 (37237)
2023 (42045)
2022 (53338)
2021 (58018)
2020 (56723)
2019 (49934)
2018 (37761)
2017 (34838)
2016 (34730)
2015 (40810)
2014 (34949)
2013 (30241)
2012 (32224)
2011 (32693)
2010 (30934)
Location
Africa (945)
Alabama (94)
Alaska (7)
Arizona (334)
Arkansas (15)
Asia (45181)
Australia (8025)
California (12051)
Canada (3441)
China (1219)
Colorado (504)
Connecticut (522)
Delaware (354)
Europe (100590)
Florida (1802)
Georgia (384)
Hawaii (3)
Idaho (65)
Illinois (959)
India (77)
Indiana (552)
Iowa (24)
Japan (466)
Kansas (132)
Kentucky (48)
Louisiana (32)
Maine (72)
Maryland (1488)
Massachusetts (8780)
Michigan (351)
Minnesota (668)
Mississippi (7)
Missouri (143)
Montana (35)
Nebraska (29)
Nevada (130)
New Hampshire (87)
New Jersey (3210)
New Mexico (32)
New York (3177)
North Carolina (1648)
North Dakota (9)
Northern California (5880)
Ohio (359)
Oklahoma (21)
Oregon (47)
Pennsylvania (2411)
Puerto Rico (25)
Rhode Island (52)
South America (1317)
South Carolina (69)
South Dakota (1)
Southern California (4691)
Tennessee (190)
Texas (1860)
United States (43060)
Utah (364)
Vermont (1)
Virginia (287)
Washington D.C. (86)
Washington State (988)
West Virginia (4)
Wisconsin (125)
Wyoming (2)
786,244 Results for "sarepta therapeutics formerly known as avi biopharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
After Sarepta’s Annus Horribilis, Elevidys Sales Expected To Continue Downward Spiral
After a rocky 2025, Sarepta Therapeutics’ executives admit they have work to do to bring patients back into the fold as sales of Duchenne muscular dystrophy gene therapy Elevidys continue to decline.
February 26, 2026
·
5 min read
·
Annalee Armstrong
Duchenne muscular dystrophy
Following Sarepta Woes, Others Look To Unlock the Next Chapter in DMD Treatment
With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor Therapeutics, CureDuchenne CSO Michael Kelly sees “momentum” in the Duchenne muscular dystrophy pipeline, as Sarepta’s Elevidys leaves the door open.
February 9, 2026
·
11 min read
·
Heather McKenzie
C-suite
Sarepta CEO Doug Ingram To Step Down as Muscular Dystrophy Mission Hits Home
When Ingram became Sarepta Therapeutics’ CEO in 2017, he didn’t have a connection to muscular dystrophy, but he has developed a fierce passion for the therapeutic area. He will step aside from his role to dedicate more time to his family.
February 25, 2026
·
2 min read
·
Annalee Armstrong
Opinion
Balancing Safety Access in Rare Disease—Lessons From Sarepta
Regulators overseeing rare disease treatments need better tools to weigh competing risks in real time. Sarepta Therapeutics’ Elevidys is a prime example of why.
February 25, 2026
·
6 min read
·
Joshua R. Mansbach
Duchenne muscular dystrophy
Sarepta’s DMD Gene Therapy Staves Off Disease Three Years After Treatment
After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing benefits of the therapy three years after dosing.
January 26, 2026
·
2 min read
·
Dan Samorodnitsky
Duchenne muscular dystrophy
Sarepta Saga Has ‘Gone on Too Long’ as Competitors Catch Up
After a series of deaths in patients taking Sarepta Therapeutics’ gene therapies, doubt has crept into investor sentiments around the long-time Wall Street darling, and patients may soon begin looking elsewhere.
February 5, 2026
·
5 min read
·
Dan Samorodnitsky
Gene therapy
After Mortality-Marred Year, Sarepta Looks Ahead to Catalyst-Rich 2026
Jefferies analysts forecast a $1 billion market opportunity for each of Sarepta’s siRNA programs for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.
January 13, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan
February 25, 2026
·
12 min read
Legal
REGENXBIO Secures Legal Win in Gene Therapy Patent Battle Vs. Sarepta
A lower court had previously ruled for Sarepta in the companies’ long-running dispute, finding that REGENXBIO’s AAV patent was invalid because its elements were naturally occurring. The appeals court on Friday said that this original decision adopts a “narrow” view of the invention.
February 23, 2026
·
2 min read
·
Tristan Manalac
Podcast
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More
Roche’s obesity candidate achieves 22.5% weight loss in Phase II; Moderna pulls the plug on late-stage vaccine trials as Health Secretary Robert F. Kennedy’s anti-vaccine policies and rhetoric continues; and embattled gene therapy maker Sarepta announces new data in Duchenne muscular dystrophy.
January 28, 2026
·
1 min read
·
Heather McKenzie
1 of 78,625
Next
